Telitacicept for IgA nephropathy: a systematic review and meta-analysis of observational studies.

What was studied

This review pooled observational studies of telitacicept in IgA nephropathy. Telitacicept blocks BAFF and APRIL. The studies compared it with other drugs that calm the immune system. It was given alone or with other drugs. They had 459 people with biopsy-confirmed illness.

What they found

Alone, telitacicept did not differ clearly from other immune drugs. This held for remission, urine protein, kidney function, creatinine and albumin. Combinations also showed no clear gaps. Alone, it had clearly fewer adverse drug reactions than control care. Certainty ranged from moderate to very low.

What it means for patients

The team says current data suggest a favorable safety profile. They say it may give clinical benefit. They say superiority in efficacy was not confirmed. They say the trend leaned toward telitacicept in several analyses.

Why it is not certain yet

All studies were observational. Certainty was moderate to very low. The team says larger, high-quality prospective studies are needed. Full data tables are not shown. Some steps of the work are not given. Details of the methods are brief. This text uses the abstract and nothing else.

Source

Telitacicept for IgA nephropathy: a systematic review and meta-analysis of observational studies.

We restate facts from the source record in our own words. The original wording belongs to its publisher.